Kurt, İdrisEdis, Ebru ÇakırMert, Habibe Tülin Elmaslar2024-06-122024-06-1220212147-2475https://doi.org/10.5505/respircase.2021.60565https://search.trdizin.gov.tr/yayin/detay/504856https://hdl.handle.net/20.500.14551/13570The new type of coronavirus (SARS-CoV2) reported to have originated in China in December 2019 has spread rapidly all over the world and has become a global problem. COVID-19 is more common and more severe in people with such comorbidities as cardiovascular disease, hypertension and diabetes. There is a lack of consensus on whether rheumato- logical diseases and drugs used in their treatment increase the risk of developing COVID-19. There is also lack of data in literature regarding the develop- ment of COVID-19, especially in patients with Anky- losing Spondylitis. This case presentation relates to two patients with Ankylosing Spondylitis using anti- TNF agents who were affected by COVID-19. The younger of the two, who had no comorbidities, healed quickly with antiviral and supportive therapy, while the older patient, who had cardiovascular and chronic kidney comorbidities, experienced an aggres- sive disease course and did not survive. The course of COVID-19 infection and mortality is strongly con- nected with underlying comorbidities. Our focus here is on rheumatological diseases, their immunosup- pressive treatments and their impact on the course of the novel type Coronavirus infection, based on two cases of Ankylosing Spondylitis, in light of literature.en10.5505/respircase.2021.60565info:eu-repo/semantics/openAccessArticle1027882504856